13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001799883
Total reported value
$287.9M
$287.9M
31 檔
66.8%
During the Q4 2024 filing period, 5AM Venture Management, LLC (CIK: 0001799883) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $287.9M across 31 reported positions.
5AM Venture Management, LLC executed strategic sector rebalancing during Q4 2024, establishing 4 new positions while fully exiting 1 holdings and trimming 6 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | TRDA | Entrada Therapeutics Inc | Stock-Other | 18.19% | -3.84% | — | |
| 2 | ELVN | Enliven Therapeutics Inc | Stock-Other | 8.75% | — | -6.99% | |
| 3 | SKYE | Skye Bioscience Inc | Stock-Other | 6.69% | +0.68% | — | |
| 4 | TECX | Tectonic Therapeutic Inc | Stock-Other | 6.57% | +2.03% | -7.71% | |
| 5 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 5.66% | +3.72% | — | |
| 6 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 5.35% | — | -16.56% | |
| 7 | BHVN | Biohaven Ltd. | Stock-Other | 4.27% | +2.08% | — | |
| 8 | PHVS | Pharvaris N.V. | Stock-Other | 3.65% | +3.32% | — | |
| 9 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 3.65% | — | — | |
| 10 | CAMP | Camp4 Therapeutics CORP | Stock-Other | 3.65% | +1.72% | — | |
| 11 | VRDN | Viridian Therapeutics Inc | Stock-Other | 3.37% | — | — | |
| 12 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 3.32% | -6.41% | EXIT | |
| 13 | ERAS | Erasca Inc | Stock-Other | 3.24% | -15.66% | EXIT | |
| 14 | PRAX | Praxis Precision Medicines I | Stock-Other | 3.12% | — | -50.00% | |
| 15 | TYRA | Tyra Biosciences Inc | Stock-Other | 3.12% | +0.48% | — | |
| 16 | CLDX | Celldex Therapeutics Inc | Stock-Other | 3.00% | +2.05% | — | |
| 17 | EYPT | Eyepoint Inc | Stock-Other | 1.87% | +1.46% | — | |
| 18 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 1.82% | — | -20.19% | |
| 19 | VOR | Vor Biopharma Inc. | Stock-Other | 1.69% | — | — | |
| 20 | ANAB | Anaptysbio Inc | Stock-Other | 1.13% | — | — | |
| 21 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.10% | — | — | |
| 22 | SCPH | Scpharmaceuticals Inc | Stock-Other | 1.01% | — | — | |
| 23 | TARA | Protara Therapeutic Inc | Stock-Other | 1.01% | -0.16% | — | |
| 24 | GHRS | GH Research PLC | Stock-Other | 0.96% | -2.24% | EXIT | |
| 25 | ✓ | Rallybio CORP | Stock-Other | 0.83% | — | — | |
| 26 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.78% | +1.12% | — | |
| 27 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 0.60% | — | — | |
| 28 | ALEC | Alector Inc | Stock-Other | 0.45% | — | — | |
| 29 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.45% | — | — | |
| 30 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.36% | — | — | |
| 31 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.35% | +4.09% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | CAMP | Camp4 Therapeutics CORP | +3.7% | NEW | New buy |
| 2 | TRDA | Entrada Therapeutics Inc | +3.6% | — | Unchanged |
| 3 | TECX | Tectonic Therapeutic Inc | +2.5% | -7.71% | Trim |
| 4 | AKRO | Akero Therapeutics Inc | +1.1% | NEW | New buy |
| 5 | TARA | Protara Therapeutic Inc | +1% | NEW | New buy |
| 6 | VOR | Vor Biopharma Inc. | +0.8% | — | Unchanged |
| 7 | MLTX | Moonlake Immunotherapeutics | +0.7% | — | Unchanged |
| 8 | PHVS | Pharvaris N.V. | +0.6% | — | Unchanged |
| 9 | ALEC | Alector Inc | +0.5% | NEW | New buy |
| 10 | CDTX | Cidara Therapeutics Inc | +0.2% | — | Unchanged |
| 11 | ERAS | Erasca Inc | +0.2% | — | Unchanged |
| 12 | GHRS | GH Research PLC | +0.2% | — | Unchanged |
| 13 | EYPT | Eyepoint Inc | +0.1% | — | Unchanged |
| 14 | ZNTL | Zentalis Pharmaceuticals Inc | 0% | — | Unchanged |
| 15 | ✓ | Rallybio CORP | -0.1% | — | Unchanged |
| 16 | ✓ | Mersana Therapeutics Inc | -0.1% | — | Unchanged |
| 17 | VRDN | Viridian Therapeutics Inc | -0.1% | — | Unchanged |
| 18 | SCPH | Scpharmaceuticals Inc | -0.1% | — | Unchanged |
| 19 | AVU0 | Adverum Biotechnologies Inc | -0.2% | — | Unchanged |
| 20 | CLDX | Celldex Therapeutics Inc | -0.5% | — | Unchanged |
| 21 | ELVN | Enliven Therapeutics Inc | -0.5% | -6.99% | Trim |
| 22 | BHVN | Biohaven Ltd. | -0.7% | — | Unchanged |
| 23 | PRAX | Praxis Precision Medicines I | -0.9% | -50.00% | Trim |
| 24 | 260 | Centessa Pharmaceuticals-adr | -0.9% | -35.34% | Trim |
| 25 | SLN | Silence Therapeutics Plc-adr | -1% | — | Unchanged |
| 26 | COGT | Cogent Biosciences Inc | -1.3% | EXIT | Sold out |
| 27 | VKTX | Viking Therapeutics Inc | -1.3% | -20.19% | Trim |
| 28 | SKYE | Skye Bioscience Inc | -1.3% | — | Unchanged |
| 29 | ANAB | Anaptysbio Inc | -1.4% | — | Unchanged |
| 30 | TYRA | Tyra Biosciences Inc | -1.4% | — | Unchanged |
| 31 | DNTH | Dianthus Therapeutics Inc | -1.6% | -16.56% | Trim |
| 32 | ARTV | Artiva Biotherapeutics Inc | -1.9% | — | Unchanged |
According to official SEC Form 13F filings, 5AM Venture Management, LLC reported a total U.S. public equity portfolio value of $287.9M across 31 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including TRDA, ELVN, SKYE) accounted for 66.8% of total reported equity market value during Q4 2024.
Top New Position Initiated
CAMP
市值: $15.3M
Top Position Liquidated / Trimmed
COGT
前期市值: $6.1M
During Q4 2024, 5AM Venture Management, LLC's top holdings by market value included TRDA (18.2%)、ELVN (8.8%)、SKYE (6.7%). The largest single position, TRDA, represented 18.2% of total portfolio value.
In Q4 2024, 5AM Venture Management, LLC made 11 total portfolio adjustments, initiating 4 new buys, adding to 0 positions, trimming 6 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.